The IMPA2 Knockout A-549 Polyclonal Cells are derived from A-549 human lung adenocarcinoma epithelial cells through CRISPR/Cas9-mediated disruption of the IMPA2 gene, producing a polyclonal knockout population. This heterogeneous cell pool, generated without single-cell cloning, provides a loss-of-function model ideal for studying functional consequences of abolished inositol monophosphatase 2 activity in a malignant epithelial background.
The parental A-549 cell line was established from lung adenocarcinoma tissue of a 58-year-old male and is widely employed as an in vitro model for non-small cell lung cancer, xenobiotic metabolism, and respiratory epithelial biology. Its adherent epithelial morphology and characterized signaling landscape render it a suitable host for interrogating the role of inositol recycling in cancer-relevant phenotypes.
IMPA2 encodes a magnesium-dependent inositol monophosphatase that dephosphorylates inositol-1-phosphate and inositol-4-phosphate to myo-inositol, a critical precursor for phosphatidylinositol resynthesis. Within the phosphatidylinositol signaling system, phospholipase C??-mediated hydrolysis of PIP2 generates IP3 and DAG; IP3 mobilizes intracellular calcium, while DAG activates PKC. IMPA2 sustains this cycle by regenerating myo-inositol, and its expression is regulated by PKA signaling and transcription factors SP1 and NF-Y. The enzyme is potently inhibited by lithium and cooperates with IMPA1. Disruption of IMPA2 therefore uncouples inositol salvage from PIP2 resynthesis, attenuating IP3-dependent calcium transients and DAG-PKC signaling.
In A-549 cells, IMPA2 knockout alters phosphoinositide metabolism, likely diminishing PIP2 availability and blunting IP3-driven calcium oscillations that are essential for proliferation, migration, and survival. Since lithium targets IMPA2, the knockout mimics chronic lithium treatment at the molecular level, creating a valuable tool for dissecting lithium-sensitive signaling independent of pharmacological inhibition. This model is particularly relevant for lung adenocarcinoma research, where dysregulated calcium and phosphoinositide pathways contribute to tumor progression.
These polyclonal knockout cells support a broad range of experimental applications, including calcium flux assays with fluorescent dyes, inositol phosphate quantification by HPLC or mass spectrometry, western blotting and RT-qPCR to confirm IMPA2 ablation, and functional assays such as proliferation, migration, and invasion studies. Lithium sensitivity experiments comparing wild-type and knockout populations can delineate IMPA2-dependent effects, while RNA-seq reveals global transcriptomic adaptations to impaired inositol homeostasis. For further information or custom inquiries, please contact Ascent Research.
